BioNTech Hands the Reins to a Commercial Chief as Oncology Data Redraws the Investment Case
Published on 09/21/2026 at 03:20 | Editorial boerse-global.de
BioNTech is asking its shareholders for patience, and the market is not in a generous mood. The Mainz-based biotech closed Friday at EUR 83.80, down 2.6%, as investors weighed a pipeline that is simultaneously delivering its most convincing survival data to date and absorbing one of its sharpest clinical setbacks.
The stock now trades roughly 21% below its 52-week high — a discount that already bakes in shrinking Covid revenue, mounting research costs and the uncertainty inherent in a company mid-transformation.
A Survival Signal That Deserves More Credit
The strongest argument for the bulls arrived on 14 September, when BioNTech and partner OncoC4 released Phase 3 data from the PRESERVE-003 study. In patients with pretreated squamous non-small cell lung cancer, the antibody Gotistobart achieved a median overall survival of 18.5 months. Standard chemotherapy managed just 10.0 months in the head-to-head comparison.
That is close to a doubling of survival time in a patient group that is notoriously difficult to treat — a result that, on the evidence, the current share price barely acknowledges. It also underpins the company's strategy of building viable cancer therapies that reach beyond its mRNA roots.
Should investors sell immediately? Or is it worth buying BioNTech?
The Other Side of Drug Development
Not every program is cooperating. Roughly two weeks ago, BioNTech and partner Genentech halted a Phase 2 trial of the experimental mRNA colorectal cancer vaccine Autogene Cevumeran. An independent monitoring committee concluded the treatment was unlikely to extend patient survival. Reuters reported the shares shed 7.5% on the day that news broke — a reminder that futility thresholds exist for a reason, and that no pipeline candidate is guaranteed to clear them.
Demand weakness in the vaccine business is adding to the pressure on earnings. BMO Capital Markets downgraded the stock from Outperform to Market Perform on 8 September and cut its price target to $105, citing an unexpectedly sharp erosion of Comirnaty sales, missing risk-reduction data for Pumitamig and softer expectations for the mRNA-based iNeST program. The analysts also pointed to the ongoing inventory drawdown in Germany.
Even so, writing BioNTech off as a loss-making former pandemic winner misses the fuller picture. In September, the company secured FDA approval for a Comirnaty vaccine adapted to the XFG variant, targeting risk groups and seniors. The legacy franchise is not collapsing outright — it is settling at a lower base that still throws off the cash needed to fund research.
A Leadership Handover for the Commercial Era
The most consequential shift, though, concerns who runs the company. BioNTech has named Guido Oelkers as its new chief executive, effective no later than 1 February 2027. Co-founders Ugur Sahin and Özlem Türeci will move to lead a new, independent mRNA company.
It is a logical maturation: a research-driven biotech needs a different skill set when it shifts from discovery to commercialization. The transition has also brought scrutiny to insider activity. After share sales by CEO Sahin were disclosed last Tuesday, further disposals followed under a pre-arranged trading plan set up under Rule 10b5-1, which executes transactions automatically. Following the most recent sale, Medine GmbH — the vehicle through which Sahin holds his stake — owns 39,218,111 ordinary shares.
What Investors Are Really Pricing
BioNTech sits at a valuation crossroads. The near-term outlook is cloudy, research spending is heavy, and the Covid windfall is fading. Yet the Gotistobart data suggest the oncology bet is not a leap of faith. Judging the company against its pandemic-era earnings is no longer the right yardstick; the question now is whether it can establish itself as a cancer specialist. On the strength of PRESERVE-003, that arithmetic has a credible path to working out over the medium to long term.
Ad
BioNTech Stock: New Analysis - 21 September
Fresh BioNTech information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
